| review article | Q7318358 |
| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1080/15284336.2016.1243363 |
| P698 | PubMed publication ID | 27809711 |
| P2093 | author name string | Roger Bedimo | |
| Lisa Rosenblatt | |||
| Joel Myers | |||
| P2860 | cites work | Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings | Q21144607 |
| Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro | Q24633870 | ||
| Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patients | Q27009523 | ||
| The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions | Q27860564 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860606 | ||
| Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials | Q27860735 | ||
| Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks | Q28269931 | ||
| Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies | Q30654030 | ||
| Tenofovir renal toxicity targets mitochondria of renal proximal tubules | Q33416391 | ||
| Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial | Q33880418 | ||
| Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o | Q35000905 | ||
| A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. | Q45949212 | ||
| Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients | Q46055807 | ||
| Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine | Q46599505 | ||
| Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients | Q46844791 | ||
| Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. | Q46900196 | ||
| Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents | Q48738533 | ||
| The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years | Q50156872 | ||
| Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. | Q51547763 | ||
| A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 result | Q51858597 | ||
| Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. | Q55056316 | ||
| 5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) | Q58204699 | ||
| Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings | Q35154069 | ||
| Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175). | Q35170350 | ||
| Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review | Q35186842 | ||
| Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results | Q35214141 | ||
| Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study | Q35602870 | ||
| Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults | Q35743556 | ||
| Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial | Q36170370 | ||
| Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. | Q36198650 | ||
| Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks | Q36282696 | ||
| Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. | Q36282716 | ||
| Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts | Q36813326 | ||
| Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. | Q36967076 | ||
| Association of tenofovir exposure with kidney disease risk in HIV infection | Q37077982 | ||
| Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV-1-Infected Patients in Western India | Q37376086 | ||
| Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density | Q37665151 | ||
| Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention | Q38222708 | ||
| Emerging concepts on the use of antiretroviral therapy in older adults living with HIV infection. | Q38265875 | ||
| Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis. | Q38591208 | ||
| A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz | Q38867641 | ||
| Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection | Q39570904 | ||
| Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study | Q40922158 | ||
| Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials | Q41044551 | ||
| Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study | Q41339429 | ||
| Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies | Q41643193 | ||
| Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study | Q42213339 | ||
| Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults | Q42229257 | ||
| Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial | Q42237448 | ||
| Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO). | Q42242966 | ||
| A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resul | Q42275853 | ||
| 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study | Q42280427 | ||
| Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults | Q42287616 | ||
| Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis | Q42635936 | ||
| Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study | Q42658845 | ||
| Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses | Q43092892 | ||
| Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial | Q43300648 | ||
| Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. | Q43451461 | ||
| Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study | Q44015302 | ||
| Reduced bone mineral density in HIV-infected patients: prevalence and associated factors | Q44427873 | ||
| Renal safety of tenofovir in HIV treatment-experienced patients. | Q44851246 | ||
| Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial | Q44975155 | ||
| Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. | Q45363261 | ||
| Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up | Q45400742 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tenofovir | Q155954 |
| emtricitabine | Q422604 | ||
| efavirenz | Q422645 | ||
| P304 | page(s) | 246-266 | |
| P577 | publication date | 2016-11-04 | |
| P1433 | published in | HIV Clinical Trials | Q15756361 |
| P1476 | title | Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection | |
| P478 | volume | 17 |
| Q40051440 | Diagnostic challenges of kidney diseases in HIV-infected patients. |
| Q52664377 | Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection. |
| Q52729705 | Tenofovir-Associated Bone Adverse Outcomes among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals. |
| Q90583050 | The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM |
Search more.